Please provide your email address to receive an email when new articles are posted on . Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been ...

Annual Meeting will be held in Chicago from May 29 to June 2, local time. Two registrational studies of the trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) ...

Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the U.S. drugmaker’s anti-PD-1 therapy in a ...

COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating ...

We conducted a retrospective cohort study of 414 patients with advanced NSCLC treated with pembrolizumab at a single center between 2016 and 2021. Patients received either fixed-dose or weight-based ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The combination of pembrolizumab and maintenance ...

The National Institute for Health and Care Excellence (NICE) has recommended alectinib (Alecensa) for ALK-positive non-small cell lung cancer following surgery to reduce recurrence risk. Around 100 ...

The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...

Standard of care in unresectable, locally advanced non-small cell lung cancer (NSCLC) involves chemoradiation plus a checkpoint inhibitor. This small trial found a promising progression-free survival ...

A 'lifeline' one-minute cancer injection is being rolled out to tens of thousands of patients on the NHS - the new pembrolizumab jab will save hours spent in immunotherapy ...